ER-POSITIVE HER2-NEGATIVE BREAST CANCER
Clinical trials for ER-POSITIVE HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER-POSITIVE HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ER-POSITIVE HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill may outsmart resistant breast cancer
Disease control OngoingThis study is for people with advanced hormone-positive, HER2-negative breast cancer that has a specific gene change (ESR1 mutation). Participants currently stable on standard therapy will either switch to a new oral drug (AZD9833) plus a CDK4/6 inhibitor or stay on their current…
Matched conditions: ER-POSITIVE HER2-NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New pill combo aims to slow advanced breast cancer
Disease control OngoingThis study tests a new oral drug (camizestrant) plus palbociclib against a standard treatment (anastrozole plus palbociclib) for people with ER-positive, HER2-negative advanced breast cancer who haven't had prior treatment for advanced disease. About 1,370 participants will be fo…
Matched conditions: ER-POSITIVE HER2-NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 08, 2026 12:02 UTC
-
AI reads old slides to predict breast cancer return
Knowledge-focused OngoingThis study looks at whether an artificial intelligence (AI) program can accurately predict if early-stage breast cancer will come back. Researchers will analyze stored tumor slides from 2,200 women who had ER-positive, HER2-negative breast cancer. The AI's predictions will be com…
Matched conditions: ER-POSITIVE HER2-NEGATIVE BREAST CANCER
Sponsor: Spotlight Medical • Aim: Knowledge-focused
Last updated May 15, 2026 11:55 UTC